On August 28, the company issued a semi-annual report for 2023. In the first half of 2023, the company achieved sales revenue of 2.663 billion yuan, a year-on-year decrease of 5.24 %, and achieved a net profit of 3.31 billion yuan belonging to the parent company, a year-on-year increase of 0.47 %. Weighted average return on net assets of 10.00 % ; the company 's basic earnings per share is 0.97 yuan.
In the first half of 2023, the company 's management actively adjusted its strategic direction according to the impact of the domestic and foreign market environment, paying attention to R & D investment and continuous innovation of talents ; optimize the production line, upgrade some of the original products, and increase the added value of the products ; actively explore new international markets and communicate and cooperate with multiple multinational corporations. The operating performance in the first half of 2023 is mainly due to the sharp decline in pesticide prices, and the sales growth is not enough to make up for the impact of the price decline, resulting in a decline in income ; the company 's prothioconazole products have good profitability, and the increase in sales ratio has increased the overall gross margin. At the same time, exchange earnings have a positive impact on the company 's performance. On the whole, in the first half of 2023, in the case of the overall downturn of the industry, the increase in the company 's production and sales offset some of the adverse effects, the profit contribution of new products was large, the overall performance of the company fluctuated little, and the operating conditions were relatively stable.
In the first half of 2023, the main work of the company is as follows : to complete the first phase of equity incentive reservation in 2021 and the first phase of equity incentive in 2021 ; the development route of the original drug was further clarified ; multi-faceted layout, third-party testing institutions ushered in a turning point ; strengthen online management and promote the construction process of information platform.
In the future, the company will be supported by seven core sub-strategies, such as humanistic development strategy, technology leading and continuous innovation strategy, efficient operation strategy, international market development strategy, original drug sustainable development strategy, crop technology service strategy and industrial chain layout strategy, and is committed to becoming the leader of the global agrochemical industry.
